Nevirapine Accord

Nevirapine, the active ingredient in Nevirapine Accord, is a Non-nucleoside reverse transcriptase inhibitor (NNRTI) presented as an oral tablet for oral use. It treats HIV-1 infection in adults and children. GNH USA supplies Nevirapine Accord as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nevirapine is an antiretroviral drug that targets the HIV‑1 reverse transcriptase enzyme, forming part of combination therapy for HIV infection. - Adult HIV-1 infection: reduces viral load when used with other antiretrovirals. - Pediatric HIV-1 infection: helps control viral replication in children. - Treatment‑experienced HIV-1 infection: provides an alternative NNRTI option in combination regimens.

Nevirapine may cause a range of adverse reactions, from mild to severe. Monitoring and prompt reporting of symptoms are essential.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Nausea: occasional upset stomach. - Fatigue: feeling unusually tired. - Headache: mild to moderate intensity. - Dizziness: occasional light‑headedness. - Abdominal pain: mild discomfort.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Hepatic failure: signs of liver dysfunction such as jaundice. - Severe hypersensitivity: including fever and swollen lymph nodes. - Neutropenia: low white‑blood‑cell count increasing infection risk. - Elevated liver enzymes: indicating possible liver injury. - Life‑threatening skin reactions: such as toxic epidermal necrolysis.

Nevirapine requires careful monitoring due to potential hepatic and dermatologic risks. - Liver function monitoring: assess baseline enzymes and repeat periodically. - Skin reactions: discontinue immediately if severe rash or mucosal involvement occurs. - Hepatic impairment: use with caution in patients with existing liver disease. - Pregnancy: risk unknown; evaluate benefits versus potential risks. - Drug resistance: avoid using as monotherapy to prevent resistance development. - Store at ambient temperature: keep in original container, protect from moisture and light.

Nevirapine interacts with several drug classes, affecting its plasma levels and safety profile.

Major Interactions (Avoid): - Ritonavir‑boosted protease inhibitors: can increase nevirapine concentrations. - Efavirenz: may reduce nevirapine exposure, compromising efficacy. - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): lower nevirapine levels.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may affect absorption; separate dosing by at least 2 hours. - Warfarin: monitor INR closely as nevirapine can alter anticoagulant effect. - Methadone: may require dose adjustment due to altered metabolism.